Literature DB >> 30666965

Incidence and in-hospital safety outcomes of patients undergoing percutaneous mitral valve edge-to-edge repair using MitraClip: five-year German national patient sample including 13,575 implants.

Ralph Stephan von Bardeleben1, Lukas Hobohm, Felix Kreidel, Mir A Ostad, Eberhard Schulz, Stavros Konstantinides, Mareike Lankeit, Ted Feldman, Thomas Münzel, Karsten Keller.   

Abstract

AIMS: The number of percutaneous edge-to-edge mitral regurgitation valve repairs with MitraClip implantation has increased during recent years. Published studies showed promising safety outcomes in relatively small cohorts, while results from large samples are sparse. Thus, we aimed to evaluate trends and safety outcomes in the German nationwide in-patient sample. METHODS AND
RESULTS: We analysed data on patients' characteristics and in-hospital safety outcomes for all percutaneous mitral valve repairs using the MitraClip technique in Germany between 2011 and 2015. Overall, 13,575 in-patients were included. The annual number of MitraClip implantations increased from 815 in 2011 to 4,432 in 2015 (β 1.00 [95% CI: 0.96-1.03], p<0.001). The in-hospital mortality (p=0.193) and major adverse cardiac and cerebrovascular events (MACCE) (p=0.183) rate remained unchanged. Important independent predictors of in-hospital mortality were heart failure (OR 1.91 [95% CI: 1.43-2.54], p<0.001), transfusion of erythrocyte concentrates (OR 9.04 [95% CI: 7.45-10.96], p<0.001), stroke (OR 6.82 [95% CI: 4.34-10.72], p<0.001), endocarditis (OR 19.52 [95% CI: 9.04-42.14], p<0.001), pulmonary embolism (OR 7.61 [95% CI: 3.44-16.81], p<0.001), pericardial tamponade (OR 14.08 [95% CI: 7.09-27.96], p<0.001) and pericardial effusion (OR 2.59 [95% CI: 1.66-4.04], p<0.001).
CONCLUSIONS: MitraClip implantations increased markedly (5.4-fold) between 2011 and 2015, with a constant in-hospital mortality and MACCE rate. Our data indicate that edge-to-edge mitral valve repair using the MitraClip technique has acceptable in-hospital safety outcomes in a real-world scenario.

Entities:  

Mesh:

Year:  2019        PMID: 30666965     DOI: 10.4244/EIJ-D-18-00961

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  6 in total

1.  Outcomes after Transcatheter Mitral Valve Edge to Edge Repair; a Comparison of Two Pathologies.

Authors:  Haytham El-Shurafa; Monirah Albabtain; Amr Arafat; Weam Abdulsalam; Juan Alfonso; Khalifa Ashmeik; Aijaz Shah; Mohammad AlOtaiby
Journal:  Acta Cardiol Sin       Date:  2021-05       Impact factor: 2.672

Review 2.  Percutaneous Mitral Valve Repair: Multi-Modality Cardiac Imaging for Patient Selection and Intra-Procedural Guidance.

Authors:  Omar K Khalique; Rebecca T Hahn
Journal:  Front Cardiovasc Med       Date:  2019-09-20

3.  Transcatheter mitral valve repair in nonagenarians.

Authors:  Pedro Luis Cepas-Guillén; Isaac Pascual; Eulogio Garcia; Pilar Jimenez-Quevedo; Alfonso Jurado-Roman; Tomás Benito-González; Rodrigo Estevez-Loureiro; Pedro Li; Dabit Arzamendi; Bruno Melica; Eduardo Infante de Oliveira; Pedro Martín Lorenzo; Felipe Fernández-Vázquez; Guillermo Galeote; Luis Nombela-Franco; Leire Unzue; Pablo Avanzas; Manel Sabate; Xavier Freixa
Journal:  J Geriatr Cardiol       Date:  2022-01-28       Impact factor: 3.327

Review 4.  Complications of the Percutaneous Mitral Valve Edge-To-Edge Repair: Role of Transesophageal Echocardiography.

Authors:  Guisela Flores; Dolores Mesa; Soledad Ojeda; Javier Suárez de Lezo; Rafael Gonzalez-Manzanares; Guillermo Dueñas; Manuel Pan
Journal:  J Clin Med       Date:  2022-08-14       Impact factor: 4.964

5.  Two year outcome in nonagenarians undergoing percutaneous mitral valve repair.

Authors:  Aikaterini Christidi; Jafer Haschemi; Maximilian Spieker; Florian Bönner; Malte Kelm; Ralf Westenfeld; Patrick Horn
Journal:  ESC Heart Fail       Date:  2020-12-06

Review 6.  Complications Following MitraClip Implantation.

Authors:  Katharina Schnitzler; Michaela Hell; Martin Geyer; Felix Kreidel; Thomas Münzel; Ralph Stephan von Bardeleben
Journal:  Curr Cardiol Rep       Date:  2021-08-13       Impact factor: 2.931

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.